Tempest Therapeutics announced the immediate resignation of Chief Financial Officer Constance Ames and the concurrent appointment of Stephanie Horn-Warnock as her successor, effective October 26, 2026. Ms. Ames's departure was for personal reasons unrelated to the company.

Key Details

  • Executive Transition: Constance Ames resigned as CFO, effective immediately on October 26, 2026.
  • New Appointment: Stephanie Horn-Warnock was appointed as the new Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, also effective October 26, 2026.
  • Compensation Terms: Ms. Horn-Warnock will serve as a consultant at a rate of $450 per hour, plus expenses and a 5.0% indirect cost allocation on professional fees.
  • Background: Ms. Horn-Warnock brings over 14 years of financial experience in the healthcare and pharmaceutical industries, most recently in leadership and consulting roles through Stout Risius Ross, LLC.